**Table S1:** Description of data augmentation for 5FU and sunitinib

|  |  |
| --- | --- |
| Variable | Distribution / Calculation |
| Both compounds |
| WT and HGT | Multivariate lognormal distribution |
| Sex | Binomial distribution |
| Age | Normal distribution |
| Time after dose | Normal distribution (excluding intake breaks for sunitinib) |
| 5FU specifics  |
| Infusion duration | 24 h assumed |
| LBM | Hume formula$$LBM=0.32810\*WT+0.33929\*HGT-29.5336 (male)$$$$LBM=0.29569\*WT+0.41813\*HGT-43.2933 (female)$$ |
| BSA | Du Bois and Du Bois formula$$BSA=0.007184\*(HGT \left(cm\right)^{0.725}\*WT \left(kg\right)^{0.425}$$ |
| Dose | Linear regression between body surface area and dose |
| 5FU Concentration | Simulated from PK model |
| Sunitinib specifics |  |
| BSA | Mosteller formula$$BSA= \sqrt{\frac{(WT\*HGT)}{3600}}$$ |
| Dose | 50 mg (standard starting dose for gastrointestinal and renal cell carcinomas [source] |
| Sunitinib and metabolite concentrations, biomarker concentrations | Simulated from PK and PD models |

Abbreviations: WT, Weight; HT, Height; BSA, Body surface area; LBM, Lean body mass